One of those conditions is sepsis. More patients die from sepsis than AIDS, prostate cancer and breast cancer combined. Early diagnosis is essential to fight conditions like sepsis, but biochemical limitations mean that patients often get caught too late.
Dascena develops algorithms as a new category of diagnostics to catch patients earlier when they can be effectively treated.
Dascena was founded in 2015 with a mission to establish statistical algorithms as a new category of diagnostic tools and bring clinical practice to new heights of quality, precision, effectiveness, and affordability.
Our flagship offering, InSight, is the first to leverage machine-learning techniques to enable early diagnosis of sepsis. Today InSight acts as many hospitals’ front line in the fight against sepsis, helping save lives and reduce healthcare costs.
Dascena is committed to advancing precision medicine and building towards a future where there are no more avoidable patient deaths due to late diagnosis.
Our founder, Ritankar Das, began developing algorithms to help diagnose complex clinical conditions while a PhD student at the University of Cambridge. His mentor, Dr. P. Roy Vagelos, encouraged him to start a company in order to bring these life-saving algorithms to patients, and became our first investor. Subsequently, the company received four grants from the National Institutes of Health (NIH) to develop the technology and perform clinical trials. Today, our algorithms are used by over 50,000 clinicians and helps save thousands of lives.
Founder, Chief Executive Officer
Ritankar Das founded Dascena at the age of 19, while a PhD student and Gates scholar at the University of Cambridge. Ritankar has published over twenty peer-reviewed publications, and is the youngest principal investigator to receive research funding from the National Institutes of Health. He holds an MSc in biomedical engineering from Oxford University as well as a BS in bioengineering and a BS in chemical biology from the University of California, Berkeley, where he received the University Medal.
Director, Clinical Development
Christopher W. Barton oversees clinical development at Dascena. Prior to joining Dascena, Chris was the Chief of Service and Vice Chair at the Department of Emergency Medicine at the University of California, San Francisco (UCSF). Chris served on the UCSF faculty for twenty-three years. Chris received his MD from the University of California, San Francisco, and completed healthcare management executive education at the Harvard Business School.
Director, Scientific Communications
Jana L. Hoffman oversees scientific communications at Dascena. Jana joined Dascena in 2015 from Catalyst Biosciences, where she held roles of increasing responsibility on the scientific team. Prior to Catalyst Biosciences, she was a postdoc in the Kuo lab at Stanford, where she discovered a previously unknown function of the vascular endothelial growth factor (VEGF) as a repressor of hepatic erythropoetin expression. Jana holds a PhD in biophysical chemistry from the University of California, Berkeley and a BA in chemistry from Princeton University.